Moderna (MRNA) Deferred Taxes (2021 - 2023)

Moderna (MRNA) has reported Deferred Taxes for 3 consecutive years, with -$33.0 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Deferred Taxes rose 68.57% year-over-year to -$33.0 million in Q4 2023; TTM through Sep 2024 was -$33.0 million, a 103.98% decrease from a year earlier, with the FY2023 full-year figure at $901.0 million, up 255.88% from the prior year.
• Deferred Taxes was -$33.0 million for Q4 2023 at Moderna, down from $1.5 billion in the prior quarter.
• Over five years, Deferred Taxes peaked at $1.5 billion in Q3 2023 and troughed at -$310.0 million in Q1 2023.
• A 3-year average of $416666.7 and a median of -$101.0 million in 2022 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes plunged 945.45% in 2022 and surged 1609.28% in 2023, its largest moves.
• Over 3 years, Deferred Taxes stood at -$229.0 million in 2021, then jumped by 54.15% to -$105.0 million in 2022, then jumped by 68.57% to -$33.0 million in 2023.
• The last three Deferred Taxes figures came in at -$33.0 million (Q4 2023), $1.5 billion (Q3 2023), and -$220.0 million (Q2 2023), per Business Quant data.